A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed on Regimens Containing ABC/3TC

Trial Profile

A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed on Regimens Containing ABC/3TC

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Emtricitabine/tenofovir alafenamide (Primary) ; Lamivudine/abacavir
  • Indications HIV infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 07 Dec 2016 Planned End Date changed from 1 Jun 2018 to 1 Mar 2018.
    • 07 Dec 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Apr 2017.
    • 07 Dec 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top